EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials

Zhaoyang Li, Alex Ballesteros-Perez

Immunotherapy Advances · 2025-12-31 · 6 (1)

DOI: 10.1093/immadv/ltag022 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction Facilitated subcutaneous immunoglobulin (fSCIG) 10% is approved for the treatment of primary immunodeficiency (PID) in both pediatric and adult patients. However, it remains unclear whether there is a clinically meaningful difference in the pharmacokinetics (PK) of immunoglobulin G (IgG) between these two populations. Methods Serum total IgG concentrations in pediatric and adult patients (aged 3–80 years) with PID from three phase 3 clinical trials of fSCIG 10% were analyzed (NCT00814320, NCT01175213, NCT03277313). Serum total IgG trough concentrations (Ctrough) were compared against the conservative threshold for treatment effectiveness of 7 g/l, and between adult and pediatric patients (aged 2 to <17 years) and pediatric subgroups (2 to <12 years and 12 to <17 years). PK parameters, including steady-state maximum concentration (Cmax), area under the curve during the dosing interval, normalized by week (AUC/week), and apparent clearance normalized for body weight (CL/F/BW), were also compared across age groups. Results All age groups effectively achieved mean IgG Ctrough above 7 g/l following fSCIG 10% administration. Total IgG exposures (mean Ctrough, Cmax, and AUC/week) marginally increased with age (all P < 0.05), while there was considerable variability within age groups. However, after total IgG baseline correction, there were no differences in any exposure parameters by age. CL/F/BW remained consistent across studies and age groups. Conclusion fSCIG 10% effectively maintains Ctrough in IgG treatment-experienced patients with PID. The small age-related differences observed in serum total IgG PK are unlikely to be clinically significant and dose adjustments by age alone are not warranted.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →